Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.

You may also be interested in...



Bristol Pays Tranzyme $10 Million For Collaboration For Discovery Program

Tranzyme’s first alliance with a Big Pharma should give it a cushion to advance its own pipeline, which includes two Phase II candidates.

Tranzyme Takes On Diabetic Gastroparesis With Novel Ghrelin Agonist

With Phase II efficacy data in hand for the I.V. version of its ghrelin agonist, Tranzyme Pharma has launched a Phase II safety and efficacy study of an oral outpatient formulation in patients with diabetic gastroparesis

Tranzyme Takes On Diabetic Gastroparesis With Novel Ghrelin Agonist

With Phase II efficacy data in hand for the I.V. version of its ghrelin agonist, Tranzyme Pharma has launched a Phase II safety and efficacy study of an oral outpatient formulation in patients with diabetic gastroparesis

Related Content

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel